A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib in combination with rituximab for previously treated indolent non-Hodgkin lymphomas (iNHL)

Abstract only

Saved in:
Bibliographic Details
Published inJournal of clinical oncology Vol. 32; no. 15_suppl; p. TPS8620
Main Authors Salles, Gilles A., Ervin, Thomas J., Dichmann, Robert, Ramchandren, Rod, Page, Ray D., Battini, Ramakrishna, Lawler, William E., Holes, Leanne, Adewoye, Adeboye H., De Vos, Sven
Format Journal Article
LanguageEnglish
Published 20.05.2014
Online AccessGet full text

Cover

More Information
Summary:Abstract only
ISSN:0732-183X
1527-7755
DOI:10.1200/jco.2014.32.15_suppl.tps8620